Literature DB >> 19496786

Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.

Jung-Won Kim1, Miki Akiyama, Jae-Hyun Park, Meng-Lay Lin, Arata Shimo, Tomomi Ueki, Yataro Daigo, Tatsuhiko Tsunoda, Toshihiko Nishidate, Yusuke Nakamura, Toyomasa Katagiri.   

Abstract

Breast cancer is known to be a hormone-dependent disease, and estrogens through an interaction with estrogen receptor (ER) enhance the proliferative and metastatic activity of breast tumor cells. Here we show a critical role of transactivation of BIG3, brefeldin A-inhibited guanine nucleotide-exchange protein 3, in activation of the estrogen/ER signaling in breast cancer cells. Knocking-down of BIG3 expression with small-interfering RNA (siRNA) drastically suppressed the growth of breast cancer cells. Subsequent coimmunoprecipitation and immunoblotting assays revealed an interaction of BIG3 with prohibitin 2/repressor of estrogen receptor activity (PHB2/REA). When BIG3 was absent, stimulation of estradiol caused the translocation of PHB2/REA to the nucleus, enhanced the interaction of PHB2/REA and ERalpha, and resulted in suppression of the ERalpha transcriptional activity. On the other hand, when BIG3 was present, BIG3 trapped PHB2/REA in the cytoplasm and inhibited its nuclear translocation, and caused enhancement of ERalpha transcriptional activity. Our results imply that BIG3 overexpression is one of the important mechanisms causing the activation of the estrogen/ERalpha signaling pathway in the hormone-related growth of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496786     DOI: 10.1111/j.1349-7006.2009.01209.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  26 in total

1.  A new treasure in the breast cancer gene hunt.

Authors:  Paul Spellman; Joe Gray
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440

2.  Nuclear Prohibitin3 Maintains Genome Integrity and Cell Proliferation in the Root Meristem through Minichromosome Maintenance 2.

Authors:  Ruihua Huang; Si Shu; Mengling Liu; Chao Wang; Bei Jiang; Jieming Jiang; Chengwei Yang; Shengchun Zhang
Journal:  Plant Physiol       Date:  2019-01-23       Impact factor: 8.340

Review 3.  Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.

Authors:  Min Ji Bak; Soumyasri Das Gupta; Joseph Wahler; Nanjoo Suh
Journal:  Semin Cancer Biol       Date:  2016-03-22       Impact factor: 15.707

4.  Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.

Authors:  Ping Fu; Zhiyong Yang; Leon A Bach
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

5.  BIG3 inhibits insulin granule biogenesis and insulin secretion.

Authors:  Hongyu Li; Shunhui Wei; Kenneth Cheng; Natalia V Gounko; Russell E Ericksen; Aimin Xu; Wanjin Hong; Weiping Han
Journal:  EMBO Rep       Date:  2014-04-07       Impact factor: 8.807

6.  Recent insights into the actions of IGFBP-6.

Authors:  Leon A Bach
Journal:  J Cell Commun Signal       Date:  2015-03-26       Impact factor: 5.782

7.  COMP-prohibitin 2 interaction maintains mitochondrial homeostasis and controls smooth muscle cell identity.

Authors:  Yiting Jia; Meili Wang; Chenfeng Mao; Fang Yu; Yingbao Wang; Rui Xiao; Changtao Jiang; Lemin Zheng; Qingbo Xu; Ming Zheng; Yi Fu; Qinghua Hu; Wei Kong
Journal:  Cell Death Dis       Date:  2018-06-04       Impact factor: 8.469

8.  Casein kinase 1 proteomics reveal prohibitin 2 function in molecular clock.

Authors:  Lorna S Kategaya; Aisha Hilliard; Louying Zhang; John M Asara; Louis J Ptáček; Ying-Hui Fu
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

Review 9.  Multifaceted role of prohibitin in cell survival and apoptosis.

Authors:  Ya-Ting Peng; Ping Chen; Ruo-Yun Ouyang; Lei Song
Journal:  Apoptosis       Date:  2015-09       Impact factor: 4.677

10.  WDR5 Expression Is Prognostic of Breast Cancer Outcome.

Authors:  Xiaofeng Dai; Wenwen Guo; Chunjun Zhan; Xiuxia Liu; Zhonghu Bai; Yankun Yang
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.